Fifth Annual National Congress on Health Care Compliance. Pharmaceutical Sales and Marketing: Are You Afraid to Look Under the Rocks?

Similar documents
Industry Funding of Continuing Medical Education

University of Mississippi Medical Center Interactions with Industry Representatives

Frequently Asked Questions

Track III-A. Creating Relationships with Prescription Drug Plans and Managed Care Organizations

Gifts to Referral Sources. Kim C. Stanger (11-17)

Web Seminar. Physician Payments in the "Sunshine": Implications of CMS Regulations for Business and the Future of American Health Care.

The Impact of the Fraud and Abuse Laws on Pharmaceutical Advertising and Marketing Compliance: A Manufacturer s Perspective

3. HEALTH, SAFETY AND ENVIRONMENTAL PROTECTION

Contracting with Specialty Pharmacies and Hubs 17 th Annual Pharma and Medical Device Compliance Congress. October 20, 2016

Shedding Light on the Sunshine Act

ANCILLARY services: How to Stay Out of Trouble. The neurosurgical minefield Informed consent

Evaluating and Determining Fair Market Value for KOLs. Presented by Jen Johnson, CFA August 10, 2011

Government, Industry and Health Profession Compliance Guidance: Welcome to the Era of Ethics and Transparency

Manufacturer Patient Support Initiatives: Current Practices and Recent Challenges. Andrew Ruskin Morgan Lewis

Telemedicine Fraud and Abuse Under the Microscope

Code on Global Interactions. with Healthcare Professionals

RESPIRONICS, INC. CONTRACTING WITH HEALTHCARE PROFESSIONALS OR PROVIDERS AND REFERRAL SOURCES POLICY

Dear Colleague, In the steadfast pursuit of excellence, I remain, Sincerely yours,

WHAT EVERY NEW PRACTITIONER SHOULD CONSIDER

COMPLIANCE WITH PATIENT ASSISTANCE PROGRAMS AND CO-PAY CARDS. Judd Katz JD MHA November 2016

Know, Prepare and Comply with the Sunshine Act Phase 2. John A. Murphy, III, Assistant General Counsel PhRMA August 26, 2014

Graduate Medical Education Medical Industry Interaction Policy and Procedure. December 18, 2008

Pharmaceutical Compliance Congress: State of the States

SIDE-BY-SIDE OF THE PHYSICIAN PAYMENTS SUNSHINE ACT

Structuring Specialty Pharmacy Distribution Arrangements in a Turbulent Regulatory Environment Mini Summit XVIII

Current Issues in Patient and Product Support. October 20, 2016

Employees may incur and/or submit for reimbursement only those business expenses that are consistent with Cardinal Health policy.

Healthcare Law Compliance Policies

HCP CODE: GLOBAL CODE ON INTERACTIONS WITH HEALTHCARE PROFESSIONALS

Legal Issues: Fraud and Abuse Navigating Stark and Kickback. Reece Hirsch, Esq. Jordana Schwartz, Esq. HIT Summit West March 7, 2005

Cost Report Compliance Issues for Critical Access Hospitals

Creation Date: 7/1/01 Title: Conflict of Interest Revision History:

The Physician Payments Sunshine Law and you: Building stronger industry - physician interactions

Puma Biotechnology 3Q Earnings Call Commercial Update

This policy applies to all Napo associates who may provide a meal to a healthcare professional.

Paul Lorenz, MBA Chief Executive Officer, SCVMC. Continuing Medical Education (CME) Standards for Commercial Support

NASPGHAN Mission Statement.

Federal Fraud and Abuse Enforcement in the ASC Space

A Special Type of Government Scrutiny: Pharmaceutical Manufacturer Relationships with Specialty Pharmacies: Part II

Value Propositions in Contractual Relationships:

REGULATORY ISSUES IMPACTING SUPPLY CHAIN

State Laws: Preemption, Enforcement, and Continued Requirements

Investigator Compensation: Motivation vs. Regulatory Compliance

HCCA CLINICAL PRACTICE COMPLIANCE CONFERENCE

Repay Overpayments (18 USC 1347; 42 CFR et seq.)

PHYSICIAN PAYMENTS SUNSHINE ACT (OPEN PAYMENTS) Mary Evelyn Armstrong MA, CRA Conflict of Interest Officer

Fraud and Abuse Laws. Kim C. Stanger. Compliance Bootcamp (5/18)

Contracting With Research Sites And Investigators: A Fraud And Abuse Primer

MEDICARE PRESCRIPTION DRUG PART D COMPLIANCE CONFERENCE. Reporting Requirements: Audit Preparedness for PDPs and Manufacturers

FINANCIAL CONFLICT OF INTEREST POLICY

LIFEBLOOD OF THE SUCCESSFUL PHARMACY: MARKETING, JOINT VENTURES, AND ARRANGEMENTS WITH REFERRAL SOURCES WHILE REMAINING WITHIN LEGAL PARAMETERS

7/25/2018. Government Enforcement in the Clinical Laboratory Space. The Statutes & Regulations. The Stark Law. The Stark Law.

Specialty Pharmacies. Ensuring Compliant Relationships. April 2017

Corporate Compliance Program Overview

Health Law 101: Issue-Spotting In Dealing With Health-Care Providers. by William H. Hall Jr.

College of Medicine Policy on Pharmaceutical, Medical Device, and Biotechnology. (1) Definitions. The following definitions apply to this regulation:

UVM College of Medicine Pharmaceutical Policy Q&A

Managing Financial Interests: The Anti Kickback Statute (AKS)

Conflicts of Interest

Is the Sunshine Act the. support? John P. Gonzalez Director of Publications Policy AstraZeneca

Developments in Recent Corporate Integrity Agreements (CIAs)

EXCERPT. Do the Right Thing R1112 P1112

UPMC POLICY AND PROCEDURE MANUAL

Korea Compliance Update Asia Pacific Pharmaceutical Compliance Congress Mini Summit XIII SEPTEMBER 17, 2014

Improving Integrity in Nursing Centers

Health Care Practice Center

Transfer of Value Disclosure Report as per National Legislation

KEY CHANGES IN THE FINAL PHYSICIAN PAYMENT SUNSHINE ACT REGULATIONS. Association of Corporate Counsel Legal Quick Hit May 30, 2013.

RISK SHARE AGREEMENTS

DETERMINING FAIR MARKET VALUE FOR SERVICES RENDERED BY A DESIGNATED COLLABORATING ORGANIZATION

DEPARTMENT OF HEALTH AND HUMAN SERVICES. Office of Inspector General s Use of Agreements to Protect the Integrity of Federal Health Care Programs

Device Congress. Track B: Reimbursement. How to Convince the Medical Director Your Product is Special

CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS) OPEN PAYMENT FREQUENTLY ASKED QUESTIONS (FAQ) TRACKER

HEALTH CARE FRAUD. EXPERT ANALYSIS HHS OIG Adopts New Anti-Kickback Safe Harbor and Civil Monetary Penalty Exceptions

HOSPITAL COMPLIANCE POTENTIAL IMPLICATION OF FRAUD AND ABUSE LAWS AND REGULATIONS FOR HOSPITALS

Ridgecrest Regional Hospital Compliance Manual

MONTEFIORE HEALTH SYSTEM ADMINISTRATIVE POLICY AND PROCEDURE

What is a Compliance Program?

LEO Pharma Global Methodological Note to EFPIA HCP/HCO Disclosure Requirements

Stark Law Exceptions and Anti-Kickback Safe Harbors

Merck's Ethical Operating Standards Handbook. Business Practices for U.S. Related Activities

American Academy of Orthopaedic Surgeons 2010 Annual Meeting. March 12, 2010

Mini-Summit XII: Patient Support Programs Part 2: Privacy and Pharmacovigilance Considerations

HealthWell Foundation & Our Commitment to OIG Compliance

ABPI Disclosure Methodological Note March 2017

The Patient Protection and Affordable Care Act of Enacted March, 2010

The Sunshine Act: Where it stands, where it s going and compliance implementation

Keys to Negotiating a Corporate Integrity Agreement. A Presentation to the Pharmaceutical Congress

Ensuring Compliance with the Law - Properly Structuring Innovative Marketing and Creative Joint Ventures. Top 5 Things to Know for CE:

Ensuring Compliance with the Law - Properly Structuring Innovative Marketing and Creative Joint Ventures. Clay Stribling, Esq.

FRAUD AND ABUSE LAW IMPLICATED BY COMPENSATION ARRANGEMENTS. Lee Rosebush, PharmD, RPh, MBA, JD

Physician-Vendor Relationship Compliance: Minimizing False Claims, Anti-Kickback Risks

Montefiore Medical Center Compliance Program. Welcome House Staff Orientation

Telemedicine Agreements: FMV, Commercial Reasonableness Compliance in Compensation Arrangements

PURCHASING INTERNET LEADS: SURE, IT CAN BE DONE, BUT BE VERY CAREFUL. Denise Leard, Esq Brown & Fortunato, P.C.

Bogies: Federal Anti- Kickback Law & EMS Contracting - Emerging Issues Pamela L. Johnston Foley & Lardner LLP Partner, Los Angeles.

CBI Pharmaceutical Compliance Congress Washington, D.C.

Product Reimbursement Services and Patient Assistance Programs KATHY CHAURETTE ALESSANDRO MARTUSCELLI

Physician Payment Transparency Provisions of the Affordable Care Act Sunshine 101

Disclaimer. The materials and views expressed in this presentation are the views of the presenters and not necessarily the views of Northwell Health

Transcription:

Fifth Annual National Congress on Health Care Compliance Pharmaceutical Sales and Marketing: Are You Afraid to Look Under the Rocks? Michael P. Swiatocha February 8, 2002

Agenda Introduction - The US Pharmaceutical Industry What s Under the Rocks? Compliance Program Structure Sales and Marketing Activities Assessment Methodology Q & A National Congress on Health Care Compliance 02/08/02 1

Introduction

US Pharmaceutical Industry Strategies for Revenue Growth Invest in R&D Discover and develop new and innovative products Develop new indications and line extensions Form alliances Improve productivity and reduce costs Increase share of voice in the marketplace Design and execute innovative programs in: Marketing Sales Customer Education National Congress on Health Care Compliance 02/08/02 3

US Pharmaceutical Industry Strategies for Revenue Growth Invest in R&D Discover and develop new and innovative products Develop new indications and line extensions Form alliances Improve productivity and reduce costs Increase share of voice in the marketplace Design and execute innovative programs in: Marketing Sales Customer Education National Congress on Health Care Compliance 02/08/02 4

US Pharmaceutical Industry Accelerated Growth of US Sales Reps: 1994 to 2000 Number of Representatives (000) 85 70 55 40 Contract Sales Reps Top 40 Pharma Reps 25 1994 1995 1996 1997 1998 1999 2000 Sources: Scott-Levin, Pharmaceutical Representative and WR Hambrecht + Co Estimates, 2001 National Congress on Health Care Compliance 02/08/02 5

US Pharmaceutical Industry 18 16 14 Overall Growth in Pharmaceutical Marketing Expenditures: ~ 16% Per Year ($/Billions) 12 10 8 6 4 2 Total Marketing Professional Mkting DTC Marketing Free Samples 0 1997 1998 1999 2000 (est.) Source: PhRMA Industry Profile, 2001 National Congress on Health Care Compliance 02/08/02 6

US Pharmaceutical Industry Rx Sales 1995 - $61 billion 2000 - $138 billion Marketing Spend on MDs 1995 - $5.5 billion 2000 - $13.2 billion Professional Spending in 2000 Samples - $ 7.9 billion Office-based promotion - $4.0 billion Hospital-based promotion - $770 million Sources: Scott-Levin, IMS, MedAd News, Pharmaceutical Representative and Datamonitor Plc National Congress on Health Care Compliance 02/08/02 7

US Pharmaceutical Industry Detailing remains the primary marketing tool Current marketplace estimates: 78,000 sales representatives (2X 1995) US sales force size 20 to 8000 representatives/managers 600,000 targeted physicians (static) 390,000 physicians see sales representatives $150-200 per detail Additional targets: - Nurse practitioners - Physician s assistants Sources: Scott-Levin, Pharmaceutical Representative, US Census Bureau, MedAd News and Datamonitor Plc National Congress on Health Care Compliance 02/08/02 8

US Pharmaceutical Industry Shrinking access to physicians in offices 1995 12 minutes (average time spent with sales representatives) 2000 7 minutes (average time spent with sales representatives) Improve sales force ROI Increase access to customers Entertainment-based programs - meetings and events - dinner programs Meals for office staff Gifts and business courtesies Sources: Scott-Levin, Pharmaceutical Representative, US Census Bureau and Datamonitor Plc National Congress on Health Care Compliance 02/08/02 9

Perspective for the Discussion Fraud and Abuse Anti-Kickback False Claims FDA HIPAA National Congress on Health Care Compliance 02/08/02 11

Compliance Program Structure Compliance officer and committee Written policies and procedures (including specific policies for customer activities, clinical research, consultants, grants, etc.) Education and training Internal reporting Auditing Compliance-related disciplinary policies Reporting of potential misconduct National Congress on Health Care Compliance 02/08/02 12

Sales and Marketing Activities Entertainment, meals and gifts Consulting, speaking and advisory fees Continuing medical education Off-label usage Pharmaceutical samples and free goods Partnerships Fees for detailing e-business National Congress on Health Care Compliance 02/08/02 13

Entertainment, Meals and Gifts 2000 $1.9 billion for meetings with customers 2000 314,000 events Control Standards AMA Guidelines - www.ama-assn.org/ceja Company policies and SOPs Training and communication Monitoring - initial approval - expense report - corrective action National Congress on Health Care Compliance 02/08/02 14

Entertainment, Meals and Gifts (continued) Examples of industry practices: Strict adherence to AMA guidelines Annual company-wide $ limit per physician for all entertainment, meals and gifts (multiple divisions) No annual $ limit per physician (maximum $ limit per event) Spouse/guest permitted (yes/no) Spouse/guest expense included in $ limit or 2X $ limit Annual company-wide $ limit per physician for medical textbooks (multiple divisions) Guidelines for F/T and P/T government employees $ limit per occasion for business courtesies National Congress on Health Care Compliance 02/08/02 15

Consultants, Speakers and Advisory Boards Control Standards AMA Guidelines Company policies and SOPs Training and communication Written contract signed by both parties Services are necessary and legitimate HHS OIG s List of Excluded Individuals and Entities Monitoring - aggregate compensation to individuals - FMV of payments National Congress on Health Care Compliance 02/08/02 16

Consultants, Speakers and Advisory Boards (continued) Examples of Industry Practices Managed by headquarters only Managed at regional and district levels Formal approval process (medical, legal, etc.) Payment ranges based on specific criteria and FMV Reimbursement for travel expense Incidental meals Entertainment (yes/no) National Congress on Health Care Compliance 02/08/02 17

Consultants, Speakers and Advisory Boards (continued) Issues to Consider Thought leaders and product advocates - critical to product launch - long-term relationships (consulting retainers) - clinical trials - publications - speaker programs - aggregate compensation - potential conflict of interest (P&T decision-maker) National Congress on Health Care Compliance 02/08/02 18

Continuing Medical Education Accredited and non-accredited programs Control Standards AMA Guidelines Accreditation Council for Continuing Medical Education (ACCME) Guidelines Company policies,sops, and training Written agreement signed by both parties Monitoring - initial approval - documentation (before/after) - audit third party activity National Congress on Health Care Compliance 02/08/02 19

Continuing Medical Education (continued) Examples of Industry Practices Managed at headquarters and regional levels Limited to CME accredited programs (yes/no) Non-CME managed through grants and contributions Formal approval and tracking processes Entertainment, meals and gifts subject to other policies No unrestricted grants for educational programs National Congress on Health Care Compliance 02/08/02 20

Continuing Medical Education (continued) Issues to Consider Inducements for purchase or recommendation for use of product Targeting of participants Program agenda and content Venue Vendor management Application of policy to other providers National Congress on Health Care Compliance 02/08/02 21

Off-label Usage of Pharmaceuticals Cost of new product development Access to patients for clinical trials Control Standards FDAMA safe harbor Company policies, SOPs, training and communication Management process to handle unsolicited requests Monitoring - approval process for sales promotions - customer targeting and call reporting - grants for studies and publications National Congress on Health Care Compliance 02/08/02 22

Off-label Usage of Pharmaceuticals (continued) Examples of Industry Practices Managers and representatives trained by legal Strong disciplinary policy Restricted to medical liaisons, specialty representatives and medical affairs Strict guidelines for sales representatives Documentation of requests from customers and responses National Congress on Health Care Compliance 02/08/02 23

Off-label Usage of Pharmaceuticals (continued) Issues to Consider Business plans Incentive compensation programs Thought leader and opinion leader use Support for advocacy groups Product websites cross-border visits National Congress on Health Care Compliance 02/08/02 24

Pharmaceutical Samples and Free Goods 2000 - $7.9 billion for samples Cost of doing business Control Standards PDMA requirements Company policies, SOPs, training and communication Records and reports Monitoring - high utilization - audits - corrective action National Congress on Health Care Compliance 02/08/02 25

Pharmaceutical Samples and Free Goods (continued) Examples of Industry Practices Strong internal/external management program Hardcopy/automated process Disciplinary policy Vouchers and coupons E-requests National Congress on Health Care Compliance 02/08/02 26

Pharmaceutical Samples and Free Goods (continued) Issues to Consider Patient assistance programs FMV for drug delivery devices, laboratory equipment, etc. Phase IV supplies Vendors National Congress on Health Care Compliance 02/08/02 27

Other Rocks Partnerships Fees for Detailing e-detailing National Congress on Health Care Compliance 02/08/02 28

Assessment Methodology

Assessment Methodology Phase I Step 1 Initial Information Acquisition Shelf Document Review Senior Management Interviews Contract Reviews (Optional) Five Step Process Step 2 Initial Review of Policies, Processes and Controls Company Operating Guidelines Other Relevant Documents Output of Steps 1 and 2 Baseline Assessments of Businesses Initial Profile of Processes and Controls Over Customer Activities List of Priority Activities for Phase II Phase II Management Update Step 3 Step 4 Step 5 Targeted Review of Controls Over Key Activities Additional Interviews Assessment of Processes/Controls Gap Analysis Options for Process Improvements Gaps in Compliance Controls Options for Improvements Design of On-going Monitoring Process Steering Committee Project Team Legal Counsel National Congress on Health Care Compliance 02/08/02 30

Q & A

For Further Information PricewaterhouseCoopers LLP Michael Swiatocha 973-236-4541 michael.p.swiatocha@us.pwcglobal.com National Congress on Health Care Compliance 02/08/02 32